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Abstract
Acyl-CoA dehydrogenase 9 (ACAD9) is an assembly factor for mitochondrial respiratory chain Complex I (CI), and ACAD9
mutations are recognized as a frequent cause of CI deﬁciency. ACAD9 also retains enzyme ACAD activity for long-chain fatty
acids in vitro, but the biological relevance of this function remains controversial partly because of the tissue speciﬁcity of ACAD9
expression: high in liver and neurons andminimal in skin ﬁbroblasts. In this study, we hypothesized that this enzymatic ACAD
activity is required for full fatty acid oxidation capacity in cells expressing high levels of ACAD9 and that loss of this function is
important in determining phenotype in ACAD9-deﬁcient patients. First, we conﬁrmed that HEK293 cells express ACAD9
abundantly. Then, we showed thatACAD9 knockout in HEK293 cells affected long-chain fatty acid oxidation alongwith Cl, both
of which were rescued by wild type ACAD9. Further, we evaluated whether the loss of ACAD9 enzymatic fatty acid oxidation
affects clinical severity in patients with ACAD9mutations. The effects on ACAD activity of 16 ACAD9mutations identiﬁed in 24
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patients were evaluated using a prokaryotic expression system. We showed that there was a signiﬁcant inverse correlation
between residual enzyme ACAD activity and phenotypic severity of ACAD9-deﬁcient patients. These results provide evidence
that in cells where it is strongly expressed, ACAD9 plays a physiological role in fatty acid oxidation, which contributes to the
severity of the phenotype in ACAD9-deﬁcient patients. Accordingly, treatment of ACAD9 patients should aim at counteracting
both CI and fatty acid oxidation dysfunctions.
Introduction
The acyl-CoA dehydrogenases (ACADs) are a family of ﬂavoen-
zymes that catalyze the ﬁrst step of fatty acid β-oxidation (FAO)
in mitochondria (1). Acyl-CoA dehydrogenase 9 (ACAD9) deﬁ-
ciency was originally described in three patients who had vari-
able disease phenotypes but shared aspects compatible with
FAO disorders (2). All three exhibited either absent or markedly
reduced ACAD9 protein and/or mRNA, with normal mitochon-
drial respiratory chain activities in muscle for the one patient
studied; however, the mutational basis for the defect in 2/3
cases was not identiﬁed. Subsequently, three studies of patients
with isolatedmitochondrial respiratory chain complex I (CI) deﬁ-
ciency identiﬁed recessive mutations in the ACAD9 gene (3–5).
These mutations were shown to affect CI assembly without bio-
chemical evidence of FAO dysfunction in either blood or ﬁbro-
blasts. Several additional cases of isolated CI deﬁciency
associated with recessive ACAD9 point mutations have since
been reported (6–10).
While ACAD9 has an unambiguous role in CI assembly, the
biological relevance of its function as a FAO enzyme has been
controversial. We previously showed that ACAD9 has broad sub-
strate speciﬁcity for acyl-CoAs in vitro (11). It has recently been de-
monstrated that ACAD9 contributes to the accumulation of
C14:1-carnitine in very long-chain acyl-CoA dehydrogenase
(VLCAD)-deﬁcient patient skin ﬁbroblasts, and minimally to
whole-cell FAO (12). However, the physiologic role of ACAD9 re-
mained questionable, as its reduction in normal ﬁbroblasts in-
creased whole-cell FAO. In contrast, ACAD9 has been suggested
to be a major contributor to FAO in tissues where it is highly ex-
pressed, such as the liver and central nervous system (2). In the
present work, we hypothesized that the ACAD function of
ACAD9 is required for full FAO capacity in cell types where it is
abundantly expressed and, moreover, that the loss of this FAO
function contributes to the pathophysiology of ACAD9deﬁciency.
To test this hypothesis, we followed three approaches. First, we
used transcription activator-like effector nuclease (TALEN) tech-
nology to knockout ACAD9 in HEK293 cells, which normally ex-
press abundant ACAD9, and measured FAO and CI activities.
Second, we studied FAO in ﬁbroblasts from Acadl/Acadvl double-
knockout mice. Finally, we expressed ACAD9-mutant alleles
identiﬁed in patients with CI deﬁciency in a prokaryotic system
and analyzed the ACAD activity of the recombinant proteins.
Results
ACAD9 knockout affects long-chain fatty acid oxidation
ACAD9 expression varies across tissues, with particularly high
expression in brain and liver. HEK293 cells derive fromembryonic
kidney but have been shown to have characteristics in common
with neurons (13,14), and they express high levels ofACAD9 (Sup-
plementaryMaterial, Fig. S1A and B) as comparedwith skin ﬁbro-
blasts. To further characterize the physiological contribution of
ACAD9 to FAO, we generated ACAD9-deﬁcient HEK293 cells in
which mutations were established in exon 2 of ACAD9 by non-
homologous end-joining repair of a TALEN-induced double-
strand break (Supplementary Material). Two clonal cell lines
lacking expression ofACAD9were evaluated. CloneAhad a single
allele harboring a complexmutation comprising a 62-bp deletion
including intron 1 and exon 2 sequences of ACAD9, along with a
102-bp insertion (Supplementary Material). Clone B had a 22-bp
deletion that created a frameshift in one allele, and a 15-bp in-
frame deletion in the other allele (Supplementary Material). We
conﬁrmed that ACAD9 protein was not detectable in these cells
whereas VLCAD and MCAD (medium-chain acyl-CoA dehydro-
genase) protein levels were not affected (Fig. 1A). Whole-cell
mitochondrial palmitate oxidation, deﬁned as etomoxir-sensi-
tive degradation of 3H-palmitate, and speciﬁc ACAD activity for
palmitoyl-CoA were measured in the two ACAD9 −/− clonal cell
lines. As shown in Figure 1B, both cell lines exhibited a 35–40%
decrease in whole-cell palmitate oxidation and palmitoyl-CoA
ACAD activity, thereby conﬁrming that ACAD9 normally plays a
role in long-chain FAO inHEK293 cells. Conversely, octanoate oxi-
dation was unaffected (Fig. 1C), indicating that the decrease in
palmitate oxidation was not merely a secondary effect of the de-
fective CI assembly (Fig. 2A and B). Additionally, evolutionary
conserved signaling intermediate in toll pathways (ECSIT), a
binding partner in ACAD9-mediated CI assembly, was absent in
both ACAD9-deﬁcient cell lines (Fig. 2B). Also, we veriﬁed that
both the CI and long-chain FAO defects were attributable to loss
of ACAD9 activity by re-introducing awild typeACAD9 cDNAback
into ACAD9-deﬁcient clone A and restoring ACAD9 expression.
Immunostaining veriﬁed that the wild type ACAD9 protein was
expressed at normal levels and properly targeted to mitochon-
dria (Fig. 3A). We then conﬁrmed complete rescue of long-chain
FAO (Fig. 3B) as well as the presence and activity of CI and
ECSIT protein (Fig. 3C).
ACAD9 can oxidize long-chain fatty acids in mouse
ﬁbroblasts
To evaluate the role of ACAD9 in another mammalian model, we
studied ﬁbroblasts from Acadl/Acadvl double-knockout mice.
These animals typically die shortly after birth,most likely as a re-
sult of hypothermia and hypoglycemia, thereby mimicking se-
vere (and usually fatal) neonatal onset human FAO disorders
(Keith Cox, personal communication) (15). The only persisting
long-chain FAO enzyme was ACAD9 (Fig. 4A). In contrast to
human VLCAD-deﬁcient ﬁbroblasts, these mouse ﬁbroblasts de-
ﬁcient in LCAD and VLCAD displayed ∼50% residual long-chain
FAO [residual palmitate oxidation rate (Fig. 4B) and palmitoyl-
CoA ACAD activity (Fig. 4C)] consistent with a physiologic role
for ACAD9 in FAO in these cells.
Phenotypic severity of ACAD9-deﬁcient patients
is correlated with residual enzyme ACAD activity
To study the impact of mutations in ACAD9 on ACAD9 stability
and enzyme function, we selected 16 ACAD9 alleles with point
mutations [previously reported or recently identiﬁed in 24 CI-de-
ﬁcient patients (Supplementary Material, Table S1)] and studied
them in an Escherichia coli expression system (Fig. 5). First, we
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analyzed ACAD9 stability and enzymatic activity in crude bacter-
ial extracts. Second, we puriﬁed the mutant recombinant ACAD9
proteins to study their trypsin sensitivity used as an indicator of
stability/folding. Finally, ACAD activity of the recombinant puri-
ﬁed proteins was analyzed. Western blot on cell lysates with an
anti-ACAD9 antibody showed lower levels of ACAD9 antigen for
nine mutations and levels comparable with non-mutated
ACAD9 for seven (R266Q, E413K, R417C, R469W, R518H, R532Q
and R532W). For eight alleles, the mutations were effectively
null, with no detectable dehydrogenase activity (I87N, R127Q,
A220V, R266Q, A326P, E413K, R417C andD418G). Of the remaining
eight mutant proteins, two (R532Q and R532W) exhibited ACAD9
activity indistinguishable from wild type; four (F44I, R469W,
R518C and R518H) had mildly decreased activity (70–80% com-
pared with wild type ACAD9) and two (L98S and R433Q) exhibited
low activity (15–20% of wild type ACAD9) (Fig. 5A).
Studies on the recombinant ACAD9 his-tagged puriﬁed pro-
teins largely reﬂected the results obtained with crude extracts.
Themutants found inactive in the crude extracts were all trypsin
hypersensitive (i.e. poorly folded) except for R127Q, and enzyma-
tically inactive when puriﬁed (Fig. 5B and Supplementary Mater-
ial, Fig. S2). Conversely, themutants thatwere stable and active in
the crude extracts were resistant to trypsin digestion and active
when puriﬁed (Fig. 5B and Supplementary Material, Fig. S2).
ACADs puriﬁed following prokaryotic expression often lose an
essential FAD cofactor, resulting in a decrease in measured en-
zyme activity that can be restored by incubation with excess
FAD. The trypsin digestion patterns of ACAD9 recombinant mu-
tant proteins with 20× added FAD are similar to those without
FAD (not shown), and this stability correlated well with their ac-
tivities after FAD addition (Fig. 5C and Supplementary Material,
Figure 1. Targeted gene disruption ofACAD9 in HEK293 cells selectively affects long-chain FAO and notmedium-chain FAO. (A) Cell lysates fromHEK293 cells (293), mock-
treated HEK293 cells (Mock) and twoACAD9−/− cell clones derived fromTALEN-transfected cells (clones A and B bothwithACAD9-nullmutations) were subjected to SDS–
PAGE and western blotting with the indicated antibodies. β-actin was used as control. (B) Etomoxir-sensitive palmitate oxidation rate (top) and palmitoyl-CoA
dehydrogenase activity (bottom) were determined in HEK293, mock-treated (Mock-Tx) and the two ACAD9 −/− clones (clones A and B). All values are presented as
average ± SD (n = 4 for each condition); *P < 0.05. (C) Octanoate oxidation rates were determined in HEK293 cells and TALEN-mediated ACAD9 −/− clone A. All values
are presented as average ± SD (n = 4). N.S., not signiﬁcant.
Figure 2. Targeted gene disruption of ACAD9 in HEK293 cells affects formation of
supercomplexes (A) as well as CI activity and ECSIT binding (B). (A) Mitochondria
isolated fromHEK293,mock-treated HEK293 and the twoACAD9 −/− clones A and
B were permeabilized with digitonin and resolved by BNGE (Blue Native Gel
Electrophoresis) followed by Coomassie Blue staining to visualize individual
respiratory chain complex bands (CI to IV) and supercomplexes (SC). (B) Top:
BNGE analysis of CI in-gel activity was performed in isolated mitochondria from
HEK293, mock-treated HEK293 and the two ACAD9 −/− clones A and B. Bottom:
SDS–PAGE immunodetection of ECSIT and β-actin in cell lysates from the same
cell lines.
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Fig. S2). Activity of the puriﬁed enzymes after addition of excess
FAD also correlated well with ACAD9 activity in crude bacterial
extracts.
Thus, while all 16 alleles were found in patients with CI deﬁ-
ciency, ACAD enzyme activity of mutant proteins varied from
non-detectable to normal levels and thus did not correlate with
the CI defect. This demonstrates that mutations in ACAD9 lead
to CI deﬁciency independent of their effects on ACAD enzyme
activity.
Next, we used molecular modeling of the ACAD9 point muta-
tions to identify their locations in the enzyme structure. Among
the ACADs, ACAD9 is structurally closest to VLCAD; both of them
have an extended C-terminal domain that has been linked with
innermitochondrial membrane association (11,16,17). The atom-
ic coordinates of VLCAD [PDB: 3B96, (18)] were therefore used to
predict the ACAD9 3D structure and investigate the impact of the
mutations on structure and/or function (Fig. 6). Mutations with lit-
tle or no impact onACADactivitywere all observed to be located in
the C-terminal domain of the protein. In contrast, the inactivating
mutations were all localized to the catalytic portion of the mol-
ecule, which is conserved in all mitochondrial matrix ACADs in-
cluding those that lack the membrane interacting domain.
Patients with CI deﬁciency caused by ACAD9 mutations dis-
play a broad range of clinical severity. We therefore asked
whether the dehydrogenase enzyme activity detected in the
ACAD9 prokaryotic expression system correlated with the sever-
ity of the clinical phenotype. We used the mean of both alleles’
enzyme activity, a generally accepted surrogate of in vivo activity
when modeling genotype–phenotype correlation in recessive in-
born errors of metabolism (19,20). Clinical phenotypes were clas-
siﬁed into two degrees of severity,mild or severe. Mild phenotype
(severity score = 1) was deﬁned as exercise intolerance and/or
cardiomyopathy, whereas severe phenotype (severity score = 2)
included encephalopathyand/or death before 2 years of age (Sup-
plementary Material, Table S1). In two families with two affected
siblings, the index patient died within the ﬁrst 2 years of life
(Score 2) whereas the second affected patient had a much less
severe clinical course (Score 1). In both cases, only the second
child was preventatively treated with riboﬂavin, which increased
residual CI activity in patient-derived cell lines (3), and may
have impacted clinical outcome (4) (Supplementary Material,
Table S1). Therefore, only index cases were included in the ana-
lysis. Logistic regression analysis revealed that the mean of both
alleles’ ACAD9 dehydrogenase activity as determined in the pro-
karyotic expression system signiﬁcantly predicted clinical sever-
ity (P = 0.034, estimate −0.034, SE = 0.016, Nagelkerke pseudo
R2 = 0.314). Conversely, and as previously reported (6,21–23), CI
activity was not found to be a signiﬁcant predictor of clinical
Figure 3. Long-chain FAO and CI defects are restored in ACAD9-deﬁcient cells by transfection of an ACAD9 expression vector. (A) Re-expression of ACAD9 in ACAD9 −/−
HEK293 clone A cells transfected with empty pcDNA3.1 vector (Vect) or pcDNA-ACAD9 (ACAD9). The ACAD9 antigen was visualized with green ﬂuorescently tagged
antibodies, and mitochondrial cytochrome c oxidase (COX) was visualized with red ﬂuorescently tagged antibodies. The merged image (arrow) shows co-localization
of ACAD9 and COX in mitochondria as yellow. Scale bar, 10.75 μm. (B) Etomoxir-sensitive palmitate oxidation rates were determined in pcDNA3.1 (Vect) and pcDNA-
ACAD9 (ACAD9) transfected clone A. Values are presented as average ± SD (n = 4); *P < 0.05. (C) Left panel: mitochondria isolated from TALEN-mediated ACAD9-
deﬁcient HEK293 clone A transfected with pcDNA3.1 vector (Vect) or pcDNA-ACAD9 (ACAD9) were permeabilized with digitonin and resolved by BNGE followed by
Coomassie Blue staining to visualize individual respiratory chain complex bands (CI to IV) and supercomplexes (SC). Right: BNGE analysis of CI in-gel activity was
performed in isolated mitochondria from pcDNA3.1-transfected (Vect) and pcDNA-ACAD9-transfected (ACAD9) clone A (top). Cell lysates from these two cell lines
were subjected to SDS–PAGE and western blotting with the indicated antibodies. β-actin was used as control.
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severity in ﬁbroblasts (P = 0.08, estimate −0.06, SE = 0.035, Nagelk-
erke pseudo R2 = 0.34) or skeletal muscle (P = 0.616, estimate
0.012, SE = 0.024, Nagelkerke pseudo R2 = 0.024).
Discussion
Using three model systems (human knockout cells, mouse ﬁbro-
blasts and recombinantmutants in prokaryotic cells), we provide
evidence that in cells where it is strongly expressed, ACAD9 plays
a physiological role in fatty acid oxidation that is independent of
its function as a CI assembly factor. Furthermore, the level of re-
sidual ACAD activity contributes to the severity of the clinical
phenotype in ACAD9-deﬁcient patients. In cell types such as
HEK293 (derived from an embryonic kidney peripheral neuronal
precursor cell (13) and expressing ACAD9 abundantly) or neo-
natal mouse ﬁbroblasts, the ACAD9 protein is utilized for both
CI assembly and FAO. Consistent with this observation, the re-
sidual ACAD9 protein seen following RNAi-mediated ACAD9
knockdown inHEK293 cells was previously shown to be sufﬁcient
to maintain a normal long-chain FAO rate but impacted CI as-
sembly (5). Similarly, ACAD9 knock down in VLCAD-deﬁcient
human ﬁbroblasts affects the very low residual FAO activity,
whereas over expression of an inactive ACAD9 protein rescues
CI activity (12). Both functional roles should also be important
in liver in which ACAD9 and VLCAD equally contribute to long-
chain FAO (2). In contrast, other human tissues such as muscle
or heart express only small amounts of ACAD9 protein relative
to VLCAD. They contain enough protein to mediate CI assembly
function without contributing appreciably to FAO. While the role
of FAO in the brain is not understood, ACAD9 is the only long-
chain ACAD enzyme expressed there (2) and is especially abun-
dant during fetal life (24,25). It is therefore tempting to speculate
that a deﬁciency in brain FAO contributes to the neurological
symptoms present in themost severely affected ACAD9-deﬁcient
patients. This notion is supported by our ﬁnding that ACAD9-
deﬁcient patients exhibiting neurological symptoms tended to
have ACAD9 mutations that either abolish or greatly reduce the
protein’s dehydrogenase activity. Similarly, robust expression
of ACAD9 in the fetal brainmight explainwhyour attempt to gen-
erate homozygous knockout Acad9 mice was unsuccessful, with
embryonic lethality presumably being attributable to a severe
combined defect in both ACAD9 functions (unpublished data).
Substantial ACAD9 expression in the nervous system might
also compensate a VLCAD defect and explain the absence of
neurological involvement in VLCAD-deﬁcient patients (26).
Thus, human ACAD9 deﬁciency should be viewed as a bifunc-
tional disorder in mitochondrial energy metabolism (12) with
an additional phenotypic burden in the patients bearing muta-
tions that affect both CI assembly as well as long-chain FAO.
The molecular modeling described herein offers some in-
sights into the underlying mechanisms by which different
ACAD9mutationsmediate their pathologic effects. ACAD9muta-
tions that preserved enzyme activity are located in the 176 amino
acid C-terminal domain. In VLCAD, the corresponding C-termin-
al domain interactswith innermitochondrialmembrane compo-
nents, whereas its catalytic domain mediates the interaction
with the rest of a fatty acid complex (27,28). The C-terminus of
ACAD9 likely interacts with a different molecular partner(s)
than its equivalent in VLCAD. Rather, we hypothesize that it
serves to interact with the mitochondrial inner membrane,
ECSIT, TMEM126B or CI intermediates (29). This is consistent
with the observation that mutations in the C-terminal domain
of ACAD9 affect CI assembly without impairing ACAD catalytic
activity. As ACAD9 is not highly expressed in human ﬁbroblasts,
it is not possible to directly demonstrate the effect of the C-ter-
minal ACAD9 mutations on FAO. However, we speculate that
they will retain at least some FAO activity in liver and neurons.
In contrast, mutations affecting ACAD9 enzyme function were
all localized to the ACAD catalytic domain, where they disrupt
both catalytic activity and CI assembly functions owing to more
broad effects on enzyme folding and/or stability. Such global per-
turbation in enzyme structure is consistent with previous ﬁnd-
ings regarding the effect of mutations, especially those at the
FAD binding site, on other ACADs (30–39).
Our ﬁndings suggest that treatment of the long-chain FAO de-
fect introduced by some ACAD9 mutations with interventions
such as avoidance of fasting, medium-chain triglycerides (40) or
triheptanoin anaplerotic therapy (41) should be helpful to opti-
mize long-term outcome in patients. Interestingly, riboﬂavin
has been reported to improvemuscle function and exercise toler-
ance in some ACAD9-deﬁcient patients (4) but not in others (9).
Riboﬂavin is the precursor for the FAD cofactor that is essential
for ACAD enzyme activity and stability (42). Therefore, riboﬂavin
responsiveness in ACAD9-deﬁcient patients (4) may be related
to a direct increase of the ACAD activity. In addition, it may
also stabilize the protein so as to allow a more efﬁcient CI
assembly (3).
The recognition of mitochondrial enzymes with dual func-
tions is growing, and in keeping with our ﬁndings on ACAD9,
the moonlighting function may be non-enzymatic. For example,
HSD10 operates as an enzyme in catabolism of the branched
chain amino acid isoleucine (43) but is also one of three protein
components of mitochondrial RNaseP that is required for mito-
chondrial integrity and cell survival (44). Similarly, short-chain
3-hydroxyacyl-CoA dehydrogenase is an enzyme involved in
short-chain FAO, but the major clinical consequences of its deﬁ-
ciency are due to its moonlighting inhibitory function on gluta-
mate dehydrogenase enzymatic activity in pancreatic β-cells
(45). Loss of this non-enzymatic function leads to increased
Figure 4.Mouse double-knockout Acadl −/−, Acadvl −/− (2KO) neonatal ﬁbroblasts
exhibit residual long-chain FAO capacity. (A) Cell lysates from wild type (WT) and
double-knockout mouse ﬁbroblasts (2KO) were subjected to SDS–PAGE and western
blotting with the indicated antibodies. β-actin was used as control. Etomoxir-
sensitive palmitate oxidation rates (B) and palmitoyl-CoA dehydrogenase activity
(C) were determined in WT and 2KO double-knockout mouse ﬁbroblasts. Values
are presented as average ± SD (n= 4); *P< 0.05.
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glutamate dehydrogenase activity, resulting in insulin secretion
hypersensitivity. Other proteins associated with CI also have
moonlighting functions. For example, NDUFAB1, a CI structural
subunit, has an acyl carrier protein domain involved in fatty
acid synthesis (46), and it has been suggested that some of the
CI structural subunits may act as a molecular scaffold for as yet
unrecognized enzymatic activities (47). Overall, the occurrence
of mitochondrial enzymes with dual functions is likely to be of
greater import than previously recognized. So far, in all identiﬁed
patients with ACAD9 mutations, the non-enzymatic function is
impaired whereas the FAO activity might be an important factor
in determining severity of phenotype. Better delineation of the
interplay between these functions is central for understanding
the clinical heterogeneity characteristic of many mitochondrial
metabolic disorders.
Materials and Methods
Mutagenesis and expression studies
For prokaryotic mutagenesis studies, 16 ACAD9 mutations (F44I,
I87N, L98S, R127Q, A220V, R266Q, A326P, E413K, R417C, D418G,
R433Q R469W, R518C, R518H, R532Wand R532Q) were introduced
into a pEThACAD9 expression plasmid (11) using the Quick-
Change Site-Directed Mutagenesis Kit according to themanufac-
turer’s instructions (Agilent, Santa Clara, CA, USA). Mutations
were veriﬁed by sequencing, and the plasmids were introduced
into an E. coli expression strain (BL21), cultured at 37°C and in-
duced for expression studies as previously described (27). En-
zyme activity was determined using the ETF-ﬂuorescence
reduction assay and western blotting was performed on cell-
free extracts as previously described (27,48,49). ACAD9 wild-
Figure 5. ACAD9 missense mutations affect FAO independent from its CI assembly function. (A) Prokaryotic mutagenesis and expression studies of 16 ACAD9 alleles
containing missense variants. Each allele with the predicted amino acid substitution shown at the top of the ﬁgure was expressed in E. coli, and the cell-free extract
was analyzed by SDS–PAGE followed by western blotting with anti-ACAD9 antibodies (middle). Palmitoyl-CoA dehydrogenase activity (ACAD9 activity) in cell-free
extracts following prokaryotic expression is given on the bottom line. ND: non-detectable. ACAD9 activity of each mutant protein is expressed as % of the activity of
wild-type (WT) ACAD9 expressed in E. coli. (B) SDS–PAGE analysis of recombinant wild type-His-tagged ACAD9 (WT) and two mutants ACAD9 proteins chosen as an
example (E413K, unstable and R518H, stable) during limited trypsin digestion. The molar ratio of protein to trypsin was 1000:1. The reactions were initiated by adding
trypsin into 1 mg/ml ACAD9 proteins in 25 m sodium phosphate buffer, pH 7.6, containing 100 m NaCl and 10% glycerol. Aliquots were taken at indicated times for
SDS–PAGE analysis. While band a represents the entire mature ACAD9 peptide (65 kDa), the molecular weight of bands b and c correspond to the N-terminal domain
(45 kDa) and C-terminal domain (17 kDa) of the mature ACAD9 protein, respectively. Bands b1 and b2 correspond to an additional cleavage site in the loop region
connecting N-terminal and C-terminal domain. Upon addition of trypsin, both WT, E413K and R518H mutants are quickly digested into two pieces: the N-terminal
domain (45 kDa) and the C-terminal domain (17 kDa). However, as the trypsin digestion continues, the N-terminal and C-terminal domains of E413K were further
cleaved into smaller pieces (instability), whereas the two domains of WT and R518H are very stable. (C) Comparison between crude extracts (white) and puriﬁed
protein data (gray) for each mutants. S: stability of the recombinant ACAD9 proteins from crude extracts evaluated on western blots (+++: very stable; −: very
unstable). T: stability of the recombinant puriﬁed ACAD9 proteins after trypsin proteolysis (+++: very stable; −: very unstable). C: ACAD activity of crude extract. %:
percentage of the activity of wild type recombinant ACAD9. P: speciﬁc activity of the recombinant puriﬁed ACAD9 expressed as μmole of C16-CoA oxidized/min/mg of
ACAD9 protein in the presence of added FAD. NA: not available. ND: non-detectable. MW: molecular weight.
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type and mutant proteins with C-terminal His tag (GSHHHHHH)
were similarly expressed and then puriﬁed on a His60 Ni resin
column (Clontech, Mountain View, CA, USA) per the manufac-
turer’s instructions. ACAD activity of the puriﬁed ACAD9 recom-
binant proteins was assayed using ferricenium as the ﬁnal
electron acceptor as described (50). Assays were performed both
with and without exogenous FAD (0.3 m FAD ﬁnal) added to
1 mg/ml ACAD9 protein and incubated on ice for 30 min before
the activity assay.
Limited proteolysis of puriﬁed recombinant ACAD9
by trypsin
One hundred µl of 1 mg/ml puriﬁed ACAD9 in buffer A was di-
gested with 5 µl of 7 µg/ml of Tosyl phenylalanyl chloromethyl
ketone (TPCK)-treated trypsin (ACAD9/trypsin molar ratio of
1000) in the absence and presence of 20-molar excess of exogen-
ous FAD (0.3 m FAD ﬁnal). The reaction was incubated at room
temperature. At indicated times, aliquots were removed and the
reaction was terminated by addition of SDS sample buffer and
immediately boiled for 4 min and analyzed by 12.5% SDS–PAGE
and stained with Coomassie Blue (Bio-Rad, Hercules, CA, USA).
Molecular modeling
Molecular modeling was performed using InsightII software with
homology module (Accelyrs, Inc., San Diego, CA, USA) on an SGI
Fuel workstation. The atomic coordinates used as template were
as published (PDB code 3B96) (18).
Western blotting on mammalian cells
Western blotting of total cell lysateswas performed as previously
described (51).
Antibodies
Custom-made rabbit polyclonal anti-human ECSIT antibodies
were obtained by immunization of puriﬁed recombinant ECSIT
in rabbits by Cocalico Biologicals (Reamstown, PA, USA). Anti-
ACAD9, MCAD, LCAD and VLCAD antisera were produced as
already reported (11,27).
ACAD9 activity measurement
ACAD9 activity was measured using palmitoyl-CoA as substrate
with the electron transfer ﬂavoprotein ﬂuorescence reduction
assay using 100–150 µg protein as described (48,49).
Whole-cell fatty acid oxidation analysis
Whole-cell long-chain FAOwas evaluated using a tritium release
assay with 3H-palmitate-BSA as the substrate, essentially as de-
scribed (52). Octanoate oxidation was measured using 125 µ
14C-octanoate under the same conditions, only with substrate
oxidation detected through capture of 14CO2 following acidiﬁca-
tion of the media with perchloric acid.
Preparation of mitochondria from cells, BNGE and CI in situ
activity and stainingwere performed as previously reported (53).
Complementation of the ACAD9 −/− HEK293 clone A
ACAD9 knockout HEK293 clone A cells were stably transfected
with the mammalian expression vector pcDNA3.1(+) (Invitrogen,
Grand Island, NY, USA) containing the normal human ACAD9 se-
quence with the mitochondrial precursor (11). Brieﬂy, 1–4 × 105
HEK293 clone A cells were plated in a 12-well plate containing
1 ml/well of DMEM and 10% FBS (v/v) but no antibiotics. The
next day, cells were transfected with a mixture of 1.6 µg of the
ACAD9 expression vector (or pcDNA3.1 vector as negative control),
lipofectamine and Opti-MEM, according to the manufacturer.
Selection with G418 (Roche, Boulogne-Billancourt, France) was
used at 1 mg/ml for 2–3 weeks. Maintenance concentrations of
0.4 mg/ml G418 were used for further experiments.
Confocal imaging of HEK293 cells
HEK293 (clone A transfected with ACAD9 expression vector or
empty vector) cells were seeded at a concentration of 1 × 104
cells/ml on tissue culture-treated glass cover slips and allowed
Figure 6.Molecularmodeling of theACAD9mutations. Twoperpendicular views of ribbon representations of a humanACAD9monomermodel (11) showing the active site
with bound FAD and the acyl moiety of myristoyl-CoA and the location of missense mutations found in ACAD9-deﬁcient patients. The second monomer, hidden, lies
between the C-terminus (blue) α-helix and the rest of the monomer (gray). The model was generated using the human VLCAD crystal structure coordinates
(PDB: 3B96) (18). The peptide stretch 448–494 is not represented as its equivalent in the template molecule, the VLCAD crystal, is disordered.
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to grow overnight at 37°C in a 5% CO2, 95% humidity incubator.
Confocal imaging was performed using anti-ACAD9 and anti-
cytochrome c oxidase subunit 4 antibody (Abcam, Cambridge,
MA, USA) as described previously (54).
Studies with mouse ﬁbroblasts
Acadl/Acadvl double-knockout mouse ﬁbroblasts, deﬁcient in
LCAD and VLCAD, were obtained from Dr Keith Cox (15). These
cells, generated from skin biopsies taken from double-knockout
mice immediately after birth, were cultured in standard con-
ditions. Immunoblotting, enzyme assays and BN gels were
performed as described earlier.
Statistical analysis
All statistical comparisons were done by Student’s t-test, and the
corresponding P values are provided in the ﬁgure legends.
Supplementary Material
Supplementary Material is available at HMG online.
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